Incremental cost-effectiveness of algorithm-driven genetic testing versus no testing for Maturity Onset Diabetes of the Young (MODY) in Singapore

Conclusion Our proposed algorithm-driven testing strategy for MODY is not yet cost-effective based on established benchmarks. However, as genetic testing prices continue to fall, this strategy is likely to become cost-effective in the near future.

http://jmg.bmj.com/cgi/content/short/54/11/747?rss=1

Source: Journal of Medical Genetics - October 23, 2017 Category: Genetics & Stem Cells Authors: Nguyen, H. V., Finkelstein, E. A., Mital, S., Gardner, D. S.-L. Tags: Diagnostics Source Type: research